End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.1 CNY | +2.09% | +1.77% | -3.50% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.50% | 1.67B | - | ||
+8.79% | 222B | B | ||
+23.38% | 148B | B- | ||
+33.18% | 114B | A- | ||
+4.60% | 65.69B | A- | ||
+13.03% | 51.88B | B+ | ||
+3.16% | 50.02B | B+ | ||
-4.57% | 38.81B | A | ||
-3.38% | 34.59B | - | ||
+22.36% | 31.09B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688139 Stock
- Ratings Qingdao Haier Biomedical Co.,Ltd